US Dollar: Rally pause seen as temporary – Societe Generale
Societe Generale strategists Kit Juckes and Olivier Korber argue that Dollar strength remains underpinned by robust US growth, sticky inflation and a favourable terms of trade shock versus Europe and Asia. They note the Dollar has already risen against most majors and expect USD strength to persist through the second half of 2026, despite a recent pause.
King Dollar narrative remains intact
"Our 2026 FX Outlook ‘King Dollar will return’ had a cover picture of ‘Growth’ fighting ‘The Fed’ for a chest full of dollars."
"The US economy was already out-performing European and Asian competition, but higher oil prices brought with them a terms of trade shock – positive for the US, negative for Europe and Asia."
"As a result, the mood has changed and the dollar has risen against two thirds of the other major currencies, and all but two of the G10 ones (resource-rich AUD and NOK)."
"We expect USD strength to persist through the second half of the year."
"Of the main drivers of US growth (oil, AI capex and fiscal support), only the oil price is retreating."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
